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Abstract
Objective Gastric cancer patients generally have a poor outcome, particularly those with advanced-stage disease which is
defined by the increased invasion of cancer locally and is associated with higher metastatic potential. This study aimed to
identify genes that were functional in the most fundamental hallmark of cancer, namely invasion. We then wanted to assess
their value as biomarkers of gastric cancer progression and recurrence.
Design Data from a cohort of patients profiled on cDNA expression arrays was interrogated using K-means analysis. This
genomic approach classified the data based on patterns of gene expression allowing the identification of the genes most
correlated with the invasion of GC. We evaluated the functional role of a key protein from this analysis in invasion and as a
biomarker of recurrence after curative resection.
Results Expression of secreted frizzled-related protein 4 (SFRP4) was identified as directly proportional to gastric cancer
invasion. This finding was validated in multiple, independent datasets and its functional role in invasion was also confirmed
using invasion assays. A change in serum levels of SFRP4 after curative resection, when coupled with AJCC stage, can
accurately predict the risk of disease recurrence after curative therapy in an assay we termed PredictR.
Conclusions This simple ELISA-based assay can help predict recurrence of disease after curative gastric cancer surgery
irrespective of adjuvant therapy. The results require further evaluation in a prospective trial but would help in the rational
prescription of cancer therapies and surveillance to prevent under or over treatment of patients after curative resection.
Keyword SFRP4 · Gastric cancer · Invasion · Biomarker · Recurrence

Introduction
Supplementary Information The online version contains
supplementary material available at https://doi.org/10.1007/s1012
0-020-01143-8.

Gastric cancer (GC) is the fifth most common cancer
worldwide and the third-highest cause of cancer-related
deaths [1]. In countries lacking established screening
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programs GC is often diagnosed at an advanced stage contributing to the high mortality rate. In most Western countries the overall 5 year survival rate is less than 30% [2].
Although there are a variety of prognostic measures [3,
4], the best predictor of recurrence for GC is the pathological TNM stage using the AJCC/UICC staging system.
Invasion, measured by T-stage, is a fundamental property of cancer [5, 6] and the identification of key genes
involved causally in invasion represent ideal candidates
for therapeutics and diagnostic markers for GC.
We previously utilized mRNA expression analysis of
tumour and adjacent normal samples of gastric origin to
identify molecular signatures characteristic of premalignant
lesions and of histological subtypes of GC [7]. The same
data set has been interrogated in this study and has identified
secreted frizzled-related protein 4 (SFRP4) as a gene highly
correlated with tumour invasion or T-stage. SFRP4’s role in
invasion was validated using independent gene expression
data sets, immunohistochemistry and in vitro model systems. We then exploited the secreted nature of the SFRP4
protein to develop an ELISA-based assay (SFRP4 ratio)
which, when used in conjunction with existing clinical variables, is able to predict disease recurrence in GC patients
after curative resection with a high degree of accuracy.

Materials and methods
Patients and samples
Tumour samples were collected from patients undergoing
curative resection for GC in Melbourne. Blood samples
were collected at the time of surgery and at indicated intervals post-operatively.

Microarray analysis
cDNA microarrays (GSE2669) on tumour specimens were
run previously [7]. Clinical characteristics of patient samples are described in Table S1. All continuous variables
were considered as parametric data and analysed with
ANOVA using the Benjamini–Hochberg false discovery
rate for multiple correction [8]. K-means clustering analysis did not include correction for multiple testing and was
conducted in Genespring version 4.2 (Agilent Technologies Inc., California).

Microarray Validation cohorts
Validation cohorts were selected based on their genomic
platforms and the availability of clinical information.

13

R. A. Busuttil et al.

Australian Gastric (n = 99; GSE51105) [9] (see Table S1)
and Singapore Gastric (n = 178; GSE15459)[10] cohorts
were profiled using Affymetrix U133 plus2 arrays. The
TCGA STAD gastric cohort was profiled using RNA-seq
[11].

Immunohistochemistry
Immunostaining was performed on tissue microarrary
(TMA) sections using anti-SFRP4 antibodies (1:250; provided by Lisa Horvath [12]) and the DAKO LSAB + kit
(DAKO), following the manufacturer’s protocol.

Overall survival and relapse‑free survival analysis
Australian and Singapore datasets were analysed for
Relapse-free (RFS) and overall survival (OS) using the Barcode [13] algorithm. Validation using the public database
Kaplan–Meier plotter (KMplot) [14] was performed using
default settings. OS of the TCGA dataset was interrogated
using the Survexpress portal [15].

Genes and pathways correlated with SFRP4
Genes correlated with SFRP4 were identified in the Australian and TCGA cohorts using R and the cBIOPORTAL
[16, 17] interfaces respectively. Genes with Pearson correlation ≥ 0.6 were identified and duplicate genes were removed.
Genes common to both datasets were analysed using Reactome to identify functional pathways [18].

Cell culture
The human GC cell lines AGS, SNU-1 and NCI-N87 were
obtained from the American Type Culture Collection (Rockville, MD, USA). Cells were cultured in DMEM (AGS)
or RPMI (SNU-1 and NCI-N87) supplemented with 10%
fetal bovine serum, penicillin (100 U/ml) and streptomycin
(100ug/ml) (all from Invitrogen, Carlsbad, CA). Cell lines
were verified mycoplasma negative and identities were verified using the PowerPlex HS16 System kit (Promega).

shRNA knockdown
Verified shRNA clones were obtained from the Open Biosystems pGIPz library (Victorian Centre for Functional
Genomics). shRNA-expressing lentiviral plasmids were
transfected using Lenti-X packaging vectors into HEK293T
cells (Open Biosystems). Viral containing media was collected, filtered and stored at − 80 °C. Target cells were transduced and selected using puromycin. Knockdown was confirmed using quantitative real-time PCR and Western blot.

SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence	

Western blotting
Total protein was extracted using lysis buffer(50 mM Tris
pH 8.0, 2% SDS). Western blot analysis was carried out
using standard procedures with the following antibodies:
anti-SFRP4 polyclonal antibody [R&D (AF1827) 1:10,000]
and Anti-Tubulin (Sigma, clone B-5-1-2).

Proliferation and apoptosis assays
Proliferation assays were performed by seeding 5 × 104 cells/
well in 6-well plates and cell numbers were determined daily
using the Countess (Invitrogen) system for a total of 3 days.
Apoptosis was detected using the Apoptaq kit (Chemicon)
using the manufacturer’s conditions. AGS and NCI-N87
cells were seeded directly into chamber slides whilst a cytospin was performed on SNU-1 cells to adhere them to the
slide prior to fixing in methanol.

Invasion assay
Cells were synchronized by serum starvation to prevent
proliferation during the assay. 400,000 cells in serum-free
media ± recombinant SFRP4 (0–20 nM; R&D systems)
were combined with matrigel and seeded into 8 µm pore
transwells. Media containing serum was added to the bottom chamber as a chemoattractant and incubated for 24 h at
37 °C/5% CO2. Migrated cells were fixed in formalin and
stained with DAPI. Membranes were mounted on slides and
quantitated by microscopy. Five microscopic fields were
counted per membrane. Each experiment was performed in
triplicate at least three times.

Wound healing (migration) assay
AGS cells were seeded in a dark-walled 96-well plate and
cultured till confluent then serum starved for 24 h. The cell
monolayer was wounded with a 1.5 × 4 mm scratch using a
robotically driven pin and growth media replaced After 24 h
cells were fixed using 2% PFA and stained with phalloidin
(Molecular Probes) and DAPI. The extent of wound healing
determined using published methods [19].

SFRP4 ELISA
SFRP4 ELISA was performed using a commercially available kit (USCNK Life Science Inc) following the manufacturer’s instructions. Samples represent unique cohorts of
pre- and post-operative specimens and with at least 3 years
follow up. A consort diagram (FigS1) details the criteria
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for sample selection. An independent validation dataset
was obtained from South Korea. Clinical characteristics
for all cohorts are detailed in Table1.

Statistical analysis
Data are expressed as mean ± SEM unless otherwise
indicated. Analysis was performed using Graphpad
prism software. K-means clustering was performed using
cDNA expression arrays using Genespring software (Agilent, USA). All analysis of Affymetrix U133 plus 2 data
was carried out using R-package. We used SFRP4 ratio
and TNM stage information as independent variables in
a binary logistic regression analysis which resulted in a
predicted probability of the combination of both variables
predicting recurrence. This was evaluated by AROC and
all analyses were performed in SPSS ver22 for Mac (IBM,
Chicago).

Results
SFRP4 expression correlates with invasion
Invasion is a necessary requirement of cancer. To identify
key genes contributing to invasion, cDNA expression array
data previously generated in our laboratory using an Australian based cohort of 65 tumours was interrogated (GSE2669;
See Table S1). T-stage was used as a measure of invasion of
GC. Expression patterns positively correlated with T-stage
were identified using the GeneSpring (Agilent Technologies Inc., California) K-means clustering algorithm. Eight
patterns (K) of gene expression were chosen where every
element on the 10.5 K array (incorporating 7383 genes) was
used.
SFRP4 has been previously identified by our group as
significantly overexpressed in GC compared to normal tissue [7] and in this study was identified as one of the most
significantly correlated genes with T-stage in this discovery
cohort (Fig. 1a) and given its secreted nature was selected
for further investigation.
A second Australian based cohort was utilised for further
validation. This cohort consisted of 99 GC cases (including
43 samples which were also profiled in the cDNA array discovery cohort) and 40 normal/premalignant samples profiled
using Affymetrix 133 plus2 arrays (GSE51105; Table S1).
The expression of SFRP4 during progression to GC was
explored(Fig. 1b). Compared to normal gastric mucosa
(n = 7) the premalignant conditions chronic gastritis (n = 22,
p = 0.0077) and intestinal metaplasia (n = 21, p = 0.0031) both
demonstrated elevated SFRP4 expression. SFRP4 expression
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Fig. 1  Identification of SFRP4 as the gene most correlated with invasion. cDNA array expression data was generated for 65 tumours of
known T-stage. a K means clustering was performed based on depth
of invasion (T stage). Overall patterns of gene expression (y-axis)
using depth of invasion as a continuous variable (x-axis) visualising all 7383 genes were generated. SFRP4 (black line) was identified as the gene most correlated with invasion in this dataset. Findings were then validated over independent platforms and datasets. b
SFRP4 expression in gastric tissues. 146 gastric tissues were profiled
using Affymetrix U133 plus 2 arrays and stratified according to tissue type. Histologically normal gastric tissues [NN (n = 7)] exhibited significantly lower SFRP4 expression than other benign tissues
[chronic gastritis (CG (n = 22); p = 0.0077)] and intestinal metaplasia
[IM (n = 23; p = 0.0031)]. Highest levels of SFRP4 expression were
observed in gastric tumour samples (n = 99; p < 0.0001). Further

analysis of the 2 histological subtypes showed SFRP4 expression
to be highest in diffuse GC (n = 39) compared to intestinal gastric
cancer (n = 50; p = 0.0004). Mann–Whitney test was used for analysis. SFRP4 expression based on T-stage was determined in (c) an
updated Australian data set of 99 tumours (p = 0.003; Kruskal–Wallis
test) and the (d) Singapore dataset (n = 178; p = 0.009 Kruskal–Wallis test) were run on Affymetrix Human U133 plus 2 arrays. Each
panel represents an individual probe for SFRP4 on the array. e The
data was also validated using the TCGA RNASeq data set (n = 255;
p = 2 × 10–5 Kruskal–Wallis test) (f) SFRP4 protein expression was
determined by IHC on a TMA. Staining was quantitated using a
semi-quantitative scale from 0 (no staining; white bar), 1 + (blue bar),
2 + (red bar) and 3 + (black bar) (h) representative images showing
staining of normal gastric mucosa and an intestinal type GC (IGC).
Images × 10 and magnified × 40

was highest in the all GC group which comprised all GC cases
(n = 99; p < 0.0001 compared to normal). Further analysis of
the GC cases showed the diffuse subtype (n = 39) had significantly higher SFRP4 expression than the intestinal subtype
(n = 50; p = 0.0004).

Increasing SFRP4 expression with T-stage was validated
in three independent GC cohorts. Analysis of the tumour
samples in the Australian cohort (described above) showed
that SFRP4 expression levels increased incrementally with
advanced T-stage (Fig. 1c; p = 0.003; Kruskal–Wallis test).
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Table 1  Clinical characteristics of ELISA cases
Pilot set

Test set

Korean set

Parameter

Recurrence

Non-recurrence

Recurrence

Non-recurrence

Recurrence

Non-recurrence

Age at surgery [years (range)]
Gender
Male
Female
Type II diabetes
Y
N
Tumour location
Cardia
Non cardia
H. pylori status
Positive
Negative
Unknown
Chemo-radiotherapy
Neo-Adjuvant
No Adjuvant
Adjuvant
Adjuvant
No Adjuvant
Adjuvant
Palliative
No Palliative
Palliative
ND
Pathology
Diffuse
Intestinal
Mixed
Adenocarcinoma
Adenosquamous
Differentiation
Well
Moderate
Poor
Undifferentiated
T stage
T1
T2
T3
T4
AJCC 6th stage
IA
IB
II
IIIA
IIIB
IV

60.7 (33–83)

67.1 (55–78)

63.6 (33–83)

64.13 (43–78)

53 (33–75)

60 (43–81)

8
3

10
3

28
8

21
10

3
3

17
5

0
11

1
12

4
32

4
27

1
5

3
19

4
7

1
12

8
28

5
26

0
6

0
22

6
4
1

6
4
3

19
9
8

17
10
4

2
2
2

3
9
10

9
2

13
0

33
3

30
1

6
0

22
0

4
7

7
6

12
24

20
11

UNK
UNK

UNK
UNK

3
8
0

N/A
N/A
N/A

19
13
4

N/A
N/A
N/A

UNK
UNK
UNK

N/A
N/A
N/A

4
6
1
0
0

3
8
0
1
1

14
12
7
2
1

8
20
1
1
1

2
3
1
0
0

15
7
0
0
0

0
4
6
1

1
4
6
2

0
10
20
6

1
10
18
2

0
2
3
1

0
5
13
4

0
3
8
0

2
4
7
0

0
5
29
2

7
11
13
0

0
0
1
5

0
1
8
13

0
1
3
5
1
1

2
2
5
2
2
0

0
1
10
16
3
6

7
7
9
4
4
0

0
0
0
0
1
5

0
0
0
4
5
13

13
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Table 1  (continued)
Pilot set
Parameter
Surgery type
Proximal gastrectomy
Distal gastrectomy
Total gastrectomy
Oesophagogastrectomy
Margins
R0
R1
Recurrence type
Local
Distant
Both
None
Time till recurrence

Test set

Korean set

Recurrence

Non-recurrence

Recurrence

Non-recurrence

Recurrence

Non-recurrence

3
4
1
3

1
6
5
1

6
11
15
4

1
14
15
1

0
0
6
0

0
15
7
0

11
0

12
1

32
4

30
1

4
2

22
0

1
5
5
0
25.6 (5.9-43.5)

0
0
0
13
N/A

3
22
11
0
21.1 (2.8-77.4)

0
0
0
31
N/A

0
5
1
0
93 (30.6-233.23)

0
0
0
22
N/A

N/A not applicable
UNK unknown

Due to the limited number of T4 samples available, these
were grouped with the T3 samples. Expression data were
obtained from 178 independent GC samples originating from
Singapore. T-stage information was available for 152 of these
cases. SFRP4 mRNA expression data for these cases is represented in Fig. 1d (p = 0.009; Kruskal–Wallis test). The STADTCGA dataset contains RNA-Seq data for 255 GC cases with
known T-stage that also significantly validated the observation
(Fig. 1e; p = 2 × 10–5; Kruskal–Wallis test. All three datasets
consistently demonstrate increasing SFRP4 expression with
more advanced T-stage.
Expression of SFRP4 protein mirrored the mRNA result.
Immunohistochemistry of SFRP4 was performed and staining
was assessed semi-quantitatively on a scale 0–3 + . Increased
SFRP4 protein expression was observed in T3 compared with
T1/T2 tumours (Fig. 1f). SFRP4 was overexpressed in the
majority of gastric cancers and absent in normal gastric tissue
(Fig. 1g).

Elevated SFRP4 mRNA expression predicts poor
prognosis
Affymetrix array-derived data were used to determine
whether tumour SFRP4 mRNA expression levels could
reliably predict prognosis. The Barcode method [13] of
analysis which uses a binary representation of expression
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data was used to classify samples as having high or low
SFRP4 mRNA expression. Relapse-free survival (RFS)
indicated that high SFRP4 mRNA expression levels were
correlated with poor prognosis and patients with low
SFRP4 expression levels had a significantly lower risk
of recurrence in both the Australian (p = 0.01; Fig. 2a)
and Singapore (p = 0.04; Fig. 2b) datasets. These findings
were also validated using the gastric cohorts in the KMplot
database (p = 0.003; Fig. 2c) [14]. Survival data were limited for the TCGA dataset with no RFS data available.
A similar analysis with overall survival as an endpoint
indicates that high SFRP4 expression correlates with poor
survival, irrespective of T-stage in all four cohorts studied
(Australian p = 0.12 Fig. 2d; Singapore p = 0.002 Fig. 2e;
KMplot gastric datasets p = 2.4 × 10–5 Fig. 2f and TCGA
STAD datasets p = 0.0336 Fig. 2g).

SFRP4 has a functional role in invasion
In view of the association with T stage, we wanted to examine the role of SFRP4 in the mechanism of invasion. shRNA
was used to knockdown SFRP4 expression in GC cell lines
AGS, SNU-1 and NCI-N87. Western blot was used to confirm knockdown of SFRP4 expression at the protein level
(Fig. S2A–C) and quantitation of knockdown is shown in
Fig. S2D–F). The best overall knockdown was observed

SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence	
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Fig. 2  Effects of SFRP4 expression on relapse free (RFS) and overall survival (OS). Samples with available survival data were classified as SFRP4 high (red) or low (black) based on mRNA expression
using the Barcode method [Australian (n = 99) and Singapore cohorts
(n = 141)] or default settings of the kmplot interface (combined
independent datasets (n = 876) or Survexpress for the TCGA STAD
cohort (n = 352). a-c Kaplan–Meier curves were generated showing
RFS. The results indicate that high SFRP4 expression levels were

correlated with poor prognosis whilst patients harbouring tumours
with low SFRP4 expression levels had a significantly lower risk of
recurrence [p = 0.01 (Australian data set); p = 0.04 (Singapore data
set); p = 0.003 (combined independent data set) log-rank test]. A
similar analysis was performed using OS as an endpoint (d) Australia
dataset p = 0.12 (e) Singapore dataset p = 0.002 (f) combined independent data set p = 2.4 × 10–5 (g) TCGA STAD dataset (p = 0.0336)

using construct #3 (Fig. 3a–f) which was then used for subsequent experiments.
Potential confounding effects of SFRP4 knockdown on
proliferation (Figs. S2G–) and apoptosis (Figs. S2I–L; Fig.
S3A) were excluded.
A critical requirement for tumour invasion is the ability of the cancer cells to penetrate the extracellular matrix
and ultimately invade into adjacent structures. We utilised
invasion assays to quantitate the ability of GC cells to
invade through matrigel in vitro. AGS cells with reduced
SFRP4 expression (AGS-SFRP4#3) exhibited a significant
(72%) reduction in invasion compared to the non-targeting
control (Fig. 3g; AGS-scramble; p = 0.0005; t test). Preincubation of knockdown cells with recombinant humanSFRP4 restored the invasion capacity of the cells to invade
back to basal levels in a dose-dependent manner (Fig.
S3B). The addition of 20 nM recombinant SFRP4 protein
to wild-type cells also significantly enhanced their ability
to invade over baseline Fig. 3g (p = 0.02; t test). This suggests the secreted form of SFRP4 can help drive invasion.

Similar results were obtained with SNU-1 (p = 0.05) and
NCI-N87 (p = 0.04; t test) cells, which also exhibited significant reduction (77% and 68% respectively) of invasive
ability after SFRP4 knockdown (Figs.3h, i, respectively).
Representative images of invasion for all cell lines tested
are shown in Fig. S3C.
Migration assays showed that reduced SFRP4 levels
inhibited the migration of AGS cells (p = 0.007; Fig. S3D).
This assay was only performed for the AGS cell line as the
other cell lines do not grow in a uniform monolayer, which
is required for this assay.
Taken together, the validation and functional data
described above suggest a functional role for secreted
SFRP4 in the invasion of GC. To further explore this gene
expression data from the Australian and TCGA cohorts was
interrogated to identify genes most correlated with SFRP4
(447 and 64 genes, respectively; Table S2 and Fig. S4A).
Genes common to both datasets (n = 53; Table S2 and Fig.
S4A) were further analysed using the Reactome Database
[18]. Five of the top 8 enriched pathways are related to
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Fig. 3  shRNA knockdown of gastric cancer cell lines. shRNA
based lentiviral constructs were used to knockdown SFRP4 expression in (a) AGS, b SNU-1 and (c) NCI-N87 gastric cell lines using
the SFRP4#3 construct and validated by Western blot. d-f Quantitation of knockdown was determined using Image J (g-i) Invasion
assays were performed using WT cells, WT cells + scramble and WT
cells + SFRP4 lentivirus. Reduction of SFRP4 expression resulted in

a significant reduction in invasive capabilities (compared to scramble controls) in all cell lines. Pre-incubation of the cells with 20 nM
recombinant human SFRP4 was able to restore the invasive ability of
the knockdown cells to wild-type levels and, in the case of AGS and
NCI-N87 cell lines was able to enhance the invasive capability of WT
cells. Data show means ± SD. of at least three independent experiments. *p < 0.05, **p < 0.01

extracellular matrix organisation, composition and degradation. (Fig. S4B).
Given that disruption of the extracellular matrix promotes
epithelial to mesenchymal transition (EMT) and ultimately
invasion the Australian cohort was used to correlate SFRP4
expression to that of key genes involved in EMT. SFRP4 was
found to be significantly positively correlated to SNAI1, SLUG,
VIM, ZEB1, ZEB2 and TWIST1 and negatively correlated to
CDH1 (Fig. S5). These findings suggest that EMT may be a
large component of the mechanism of action of SFRP4.

that serum or plasma SFRP4 levels could be used as a diagnostic test for patients with GC or as a prognostic biomarker.
SFRP4 ELISA showed a high patient-to-patient variation of
both non-cancer volunteers and GC patients with no overall
difference between the two groups (data not shown) suggesting that baseline or preoperative blood SFRP4 levels are not
a suitable for diagnosis of GC.
The role of SFRP4 in invasion and potentially metastasis
suggested a change in plasma levels within an individual
may be useful in predicting patient recurrence after curative resection. We sought to determine whether SFRP4 levels changed after curative resection when compared to an
individuals baseline level to test the change in SFRP4 level
as a biomarker of tumour recurrence. We utilised a unique
cohort of patients who had undergone curative resection and

Utility of SFRP4 as a biomarker of recurrence
Based on the finding that the secreted form of SFRP4 has
biological relevance for GC we investigated the possibility

13
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were followed for up to 10 years (mean 7.3 years in nonrecurrence cases) with serial blood samples.
The pilot phase analysed 11 patients with recurrent
disease from our Australian cohort and measured SFRP4
levels in plasma: pre-operatively (baseline-levels); postoperatively (first blood drawn post-surgery); pre-recurrence
(blood drawn before clinical diagnosis of recurrence) and;
post-recurrence (first blood drawn after clinical diagnosis
of recurrence). The control group comprised 13 patients,
matched for stage, treatment, age and gender and who had
undergone curative gastric resection with no documented
recurrence. For the control group, plasma collected: preoperatively (baseline-levels); post-operatively (first blood
drawn post-surgery) and; a time point at least 36 months
post operatively was analysed. This time point was selected
as most GC patients who recur do so within 36 months of
surgery. Patient selection criteria (Fig. S1) and clinical characteristics (Table 1) were matched in both groups.
Plasma SFRP4-levels were determined for all samples
using ELISA and were measured as a ratio against the individual patient’s baseline level, to control for individual
variation. (Fig. 4a). SFRP4 ratio was defined as the ratio of

Fig. 4  Secreted SFRP4 as a biomarker for gastric cancer. a Plasma
samples collected over a period of 36 months from a pilot cohort of
clinically matched Australian GC patients, 11 of whom ultimately
recurred (red line) and 13 who did not recur (black line) were sampled using a commercial ELISA based assay. For each patient, all
results were normalised to that of their pre-operative blood sample
(SFRP4 ratio). b The ability of SFRP4 ratio to predict recurrence
was tested in a series of patient samples collected from patients who
have previously developed recurrent disease. For each patient CEA,
CA19-9 and SFRP4 ratio levels were determined and compared using

597

the first post-operative blood SFRP4 level and the baseline
SFRP4 level for individual patients. The data indicate that
SFRP4 ratios remained constant for patients who did not
develop a recurrence of disease, whilst there was an early
and sustained increase over baseline of SFRP4 plasma ratios
in patients who ultimately recurred (Fig. 4a). There was a
clear increase in circulating SFRP4 levels in patients who
develop cancer recurrence that occurs very early after curative resection and was maintained, in some cases for years,
before the clinical diagnosis of recurrence (Fig. S6). We
propose this novel finding could be exploited as a clinical
biomarker of recurrence that would facilitate triage to more
aggressive therapy or surveillance in the high-risk group.

Comparison of SFRP4 ratio and existing
blood‑based biomarkers
There are no established prognostic or surveillance biomarkers recommended for GC. We compared SFRP4
ratio with existing clinical biomarkers for gastrointestinal cancer and upper gastrointestinal cancer, CEA and
CA19-9 respectively, to evaluate their ability to pre-empt

plasma collected pre-operatively, the first post-operative blood, pre
documented recurrence (pre-recurrence) and following clinically
confirmed recurrence (post-recurrence). Dotted lines represent the
clinically utilised cut-offs for each test (CEA; 5 ng/mL and CA19-9;
35U/mL). For SFRP4 ratio the pre-determined cut off ratio of 1.2 was
used. CEA yielded various results and was only able to predict recurrence in a small percentage of cases. CA19-9 only showed positive
results after recurrence was detected clinically. These data negate the
use of both these tests as a biomarker of GC. SFRP4 ratios hows the
promising ability to predict recurrence soon after curative resection
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and detect recurrence. Pre-operative, post-operative, prerecurrence and post-recurrence bloods from GC patients
were analysed using the standard CEA and CA19-9 testing methods performed by the Peter MacCallum Cancer
Centre Pathology service. Figure 4a shows representative
data for 3 patients. CEA and CA19-9 show limited ability
to detect existing recurrent disease prior to the clinical
diagnosis of the recurrence, which provides no clinical
advantage. SFRP4 ratio is the only marker elevated before
recurrence, often months or years before the recurrence is
clinically diagnosed.

SFRP4 ratio and AJCC combination is the most
accurate predictor of recurrence (PredictR)

Fig. 5  Development of an a test to predict recurrence of gastric cancer post resection (PredictR) (a) ROC and Logistic regression were
used to determine whether SFRP4 ratio was predictive of recurrence
independent of T-stage, N-stage and AJCC stage using an extended
validation cohort of 67 Australian GC patients (36 recurrence and
31 non-recurrence). SFRP4 ratio and AJCC stage alone were similar in predictive accuracy when used independently, however when
combined (PredictR) their accuracy was significantly improved. Odds
ratio of recurrence using SFRP4 ratio alone at a cutoff of 1.21 was

7.2 (95% CI 2.5–20.6; p < 0.001) b Area under ROC of the different
groups showing highest accuracy in the PredictR (SFRP4ratio/AJCC)
combination using a logistic regression model with 95% CI (p-value
for the difference with AJCC alone = 0.044) c This was further validated in a second independent cohort of 28 Stage III Korean patients
(Korean validation cohort) 6 recurrence and 22 non-recurrence) and
found an accuracy (AUC) of 83% using SFRP4 ratio. Odds ratio of
recurrence with SFRP4 ratio at a cutoff of 1.21 was 16 (95% CI 1.5–
171.2;p value = 0.002)
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Given the superior ability of SFRP4 ratio to predict recurrence in comparison to existing biomarkers we then sought
to determine whether this was independent of currently
accepted clinical prognosticators, namely pathological TNM
stage. Logistic regression was used to assess the role of each
of 5 different models: (i) T-stage alone; (ii ) N-stage alone;
(iii) SFRP4 ratio alone; (iv) pathological AJCC stage (7th
edition) alone and; (v) SFRP4 ratio and pathological AJCC
(7th edition) in combination using a validation cohort of
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67 clinically matched GC patients from Australia which
included the pilot group (Clinical data in Table 1).
Models of prediction were evaluated using an ROC analysis (Figs.5a, b). The SFRP4 ratio/AJCC combination was
termed PredictR and had an AUC of 85% (95%CI76–94%)
for prediction of recurrent disease whereas pathological
AJCC (the current preferred predictor of recurrence) was
77% (95%:CI 66–89%) and the p-value of this difference was
0.044. It is notable that SFRP4 ratio alone had an independent AUC of 76% (95% CI65–88%) and odds ratio 7.12 (95%
CI2.5–20.6; p < 0.001) that the combination with pathological TNM (AJCC) was additive in the prediction accuracy.
This result was further validated using a prospectively
collected series from South Korea. Based on the excellent
prognosis of these patients, we selected cases with similar clinical profiles to our Australian cohort and we used
27 South Korean AJCC stage III cases. The ROC curve
(Fig. 5c) reveals PredictR has an independent AUC of 83%
(95% CI:63–98%) for prediction of recurrence in these
patients. We performed logistic regression to determine if
SFRP4 ratio alone at a threshold value of 1.2 was predictive
of recurrence in this cohort and found an Odds Ratio of 16
(95% CI1.5–171.2; p = 0.022) independent of stage corresponding to a positive predictive probability of recurrence
using SFRP4 ratio alone of 84%.

Discussion
We have previously identified SFRP4 as consistently overexpressed in all GC subtypes when compared to corresponding normal tissue [7]. Other studies have reported similar
findings in a variety of solid cancers [12, 20–22]. Epigenetic downregulation of secreted frizzled-related proteins
and SFRP4 by promoter methylation has been described in
some cancer types [23, 24] however in GC this seems to
be restricted to the SFRP2 gene [25]. Here we show that
elevated tumour SFRP4 expression is associated with poor
prognosis in GC which was also recently reported by others
[26]. These authors used an in silico based approach to show
that overexpression of SFRP4 is correlated with poor survival in glioma, colorectal, clear cell kidney, liver, head/neck
SCC and bladder cancers but not breast, lung, pancreatic,
ovarian or oesophageal cancer, suggesting disparate roles
for this protein in different tumour contexts [26].
Here, we used multiple clinical genomic cohorts of GC
to validate the finding that SFRP4 is over-expressed in more
invasive cancers. Invasion is an important hallmark of malignancy [5, 6]. Our analysis was found to significantly predict
the risk of recurrence of patients after curative resection of
their GC. SFRP4 tumour expression was previously reported
as part of a 6-gene signature which was able to predict recurrence of GC [27]. Further, the prognostic value of SFRP4
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overexpression in resectable GC was recently validated in
archived samples from the CLASSIC trial cohort [28]. We
showed elevated SFRP4 was significantly associated with
poor overall survival in the Singapore, KMplot and TCGA
cohorts. A similar trend was also seen in the Australian
cohort but this was not significant most likely due to the
small sample size.
Despite being well known for their role as WNT modulators and tumour suppressors there is emerging evidence
that suggests the SFRPs may have alternate functions related
to the promotion of carcinogensis in a context and tumour
type-dependent manner [29]. Indeed a pan-cancer, in silico
study [26] suggests that despite their proposed roles as Wnt
antagonists SFRP2 and SFRP4 may promote processes such
as cellular invasion and metastasis. This is consistent with
our findings which show that SFRP4 expression is correlated
with T-stage. We observed that genes correlated with SFRP4
are functionally enriched for signalling and extracellular
matrix pathways both of which are disrupted during EMT,
a cellular de-differentiation process by which epithelial cells
lose cell adhesion capabilities and gain invasive properties
[30].
We find that reducing SFRP4 levels using shRNA resulted
in the reduced invasion of different subtypes of gastric cancers in vitro. This novel finding introduces a unique variation
to the treatment of cancer since we have found inhibiting
SFRP4, while not oncocidal, may be considered oncostatic
(limiting invasion and potentially metastasis).
A second novel finding describes an assay which uses
SFRP4 plasma levels in two blood samples of humans with
GC. The first is taken immediately before surgery for curative resection and the second at approximately 1 month
following surgery. The ratio of these values (SFRP4 ratio)
allows for prediction of recurrence many months or years
into the future with an early and sustained increase in SFRP4
levels observed following curative surgery in patients whose
cancer ultimately recurred. The only other use of SFRP4 as
a biomarker was in the context of Type2 diabetes mellitus
[31]. We considered the potential confounding of Type2 diabetes mellitus in our study participants and found an equivalent distribution of patients in our cohort (Table1).
There are currently no effective non-invasive prognostic
biomarkers for the early detection of GC or its recurrence
following curative resection. Pepsinogen I/II ratio [32] has
been used as a screening test in some countries but is not
useful as a surveillance tool. Currently, there are no reliable circulating biomarkers for monitoring treatment of GC.
Clinicians variably use CEA (carcinoembryonic antigen),
CA19-9 and CA72-4 as serum markers. These assays were
used mainly as diagnostic biomarkers rather than markers of
prognosis. CA72-4 was reported with significant specificity
(97%) for GC [33], but because of poor sensitivity (47%)
is not used in population-based screening or for disease
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follow-up. Our SFRP4 ratio biomarker outperforms current
serum-based tests in pre-empting recurrence many months
prior to clinical detection of recurrence. Whilst significant when used alone, the predictive value of SFRP4 ratio
is further improved with the addition AJCC staging data
obtained at the time of surgical resection. We believe this
is a major step forward in providing more precise information to patients and potentially changing their management
decisions. This observation however needs to be replicated
in prospective trials. A number of potential biomarkers for
GC, based on genetic and epigenetic changes, have been
described. However, none of these have translated into clinical use, again due to lack of sensitivity and/or specificity
(reviewed in [34, 35]).
One limitation of this study reflects the current clinical
care of GC patients after curative resection. Namely, the
guidelines for postoperative management of GC recommend
clinical follow-up but no active radiological follow-up [36]
because there is currently limited evidence suggesting that
early detection of recurrence impacts patient survival. As a
result of current clinical practice, patients within this cohort
were only investigated for recurrence after clinical suspicion.
It is conceivable that recurrence in our PredictR positive
patients may have been detected earlier if regular surveillance was the standard of care. We believe the results presented in this study warrant further clinical trial to validate
the efficacy of in a prospective cohort and we believe may
lead to practice change in GC management by allowing us
to identify patients at risk of recurrence very early and allow
targeted therapy or more intensive surveillance of that highrisk group.
In conclusion, we have shown that SFRP4 is overexpressed in the majority of gastric cancers and its high
expression leads to a poor outcome. We report for the first
time that SFRP4 functions in the cellular invasion of GC
and this is the reason for the poor prognosis and that inhibition of SFRP4 leads to abrogation of invasion in vitro. This
study also found that SFRP4 levels in patients after curative
resection of gastric cancer predicts GC recurrence at an early
stage. We hypothesise that resection of the primary tumour
triggers the establishment of a permissive environment for
pre-seeded micrometastases to begin to invade, prior to the
clinical detection, and that this evidenced by an early and
sustained increase in serum SFRP4 levels in patients who
ultimately recur. Our PredictR assay may allow triage of
patients to a high-risk group warranting more aggressive
therapy and increased surveillance. This is a step towards
precision medicine given PredictR may be used in conjunction with a companion therapeutic that could target SFRP4
inhibition. These will need to be tested in future clinical
trials to determine whether this strategy leads to improved
clinical outcomes.
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